Clinical trial
Efficacy and Safety of Once-weekly Subcutaneous UBT251 in Participants With Type 2 Diabetes - a Dose-finding Study
NCT07668388 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Once-weekly Subcutaneous UBT251 in Participants With Type 2 Diabetes - a Dose-finding Study
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- June 22, 2026
- Completion date
- November 15, 2027
- Enrollment
- 300 (estimated)
- Sites
- 70
Conditions
As the registry lists them; a condition with its own page is linked.